Skye Bioscience

SKYE · Nasdaq · United States

Share price · SKYE

$1.03-1.84 (-64.14%) 3M

close as of 2026-11-18 · 24h delayed · vol 17K (0.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SKYE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 12 Nov 2026+17.5%
  2. 10 Nov 2026+21.6%
  3. 9 Nov 2026-30.3%
  4. 16 Sep 2026-19.4%
  5. 9 Sep 2026+18.6%

    Nothing announced by SKYE that day or the session before.

  6. 19 Aug 2026-14.8%
  7. 18 Aug 2026-13.5%

    Nothing announced by SKYE that day or the session before.

  8. 17 Aug 2026-17.2%
  9. 6 Aug 2026-16.0%

    Nothing announced by SKYE that day or the session before.

  10. 22 May 2026+15.9%

Share of unusual movement by asset

For each asset, the share of SKYE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
nimacimab
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—13%
Other company news (earnings, financing, releases naming no asset)—11%
Sessions with no dated event—76%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
CB1 receptorMonoclonal antibody
Obesity

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

6 October 2025Topline resultnimacimabCBeyond Phase 2a topline: nimacimab monotherapy missed the primary weight-loss endpoint
Skye Bioscience · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$1.3M$4.8M+ $0 short-term inv.—-$5.1M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$3.9M$8.1M+ $2.0M short-term inv.$11M-$7.1M operating cash flowreport ↗
2026-Q1—$7.9M$8.2M+ $9.0M short-term inv.$13M-$8.6M operating cash flowreport ↗
2025-Q3—$9.4M$18M+ $17M short-term inv.$13M-$13M operating cash flowreport ↗
2025-Q2—$14M$24M+ $25M short-term inv.$18M-$11M operating cash flowreport ↗
2025-Q1—$7.2M$46M+ $13M short-term inv.$11M-$9.2M operating cash flowreport ↗
2024-Q3—$4.9M$76M$3.9M-$5.3M operating cash flowreport ↗
2024-Q2—$4.1M$83M$7.9M-$7.1M operating cash flowreport ↗
2024-Q1—$1.9M$92M$5.0M-$4.7M operating cash flowreport ↗
2023-Q3—$1.3M$14M$25M-$4.0M operating cash flowreport ↗
2023-Q2—$1.8M$0.6M$3.1M-$2.0M operating cash flowreport ↗
2023-Q1—$1.2M$2.7M$5.2M-$4.1M operating cash flowreport ↗
2022-Q3—$1.8M$0.4M$3.1M-$2.1M operating cash flowreport ↗
2022-Q2——$2.9M$3.4M-$2.9M operating cash flowreport ↗
2022-Q1——$6.0M$3.0M-$2.9M operating cash flowreport ↗
2021-Q3——$11M$1.8M-$1.5M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$42M$5.9M+ $20M short-term inv.$14M-$43M operating cash flowreport ↗

Skye Bioscience reported no revenue for fiscal year 2025. R&D spend was $42.36M, up 126.5% YoY from $18.7M. Cash and equivalents totaled $5.88M, with a net loss of $55.92M and a quarterly net burn of $55.92M.

During the year, the company advanced nimacimab; the CBeyond Phase 2a trial showed the 200 mg monotherapy did not meet its primary endpoint, while the combination with semaglutide achieved -13.2% versus -10.25% weight loss (p=0.0372) with a favorable safety profile. Interim extension data showed 52-week mean weight loss of 22.3% in the combination arm. The company initiated a Phase 2a expansion study (Part C) evaluating intravenous nimacimab, with topline data expected in the fourth quarter of 2026, and full extension topline data expected in the third quarter of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$19M$68M+ $0 short-term inv.$6.6M-$25M operating cash flowreport ↗
2023-FY—$5.8M$10M$9.4M-$14M operating cash flowreport ↗
2022-FY—$6.0M$1.3M$4.9M-$13M operating cash flowreport ↗
2021-FY——$9.0M$2.1M-$6.5M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 30 sales ($889K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-235AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale114,851$1.61$185KForm 4
2026-09-23Schwab Andrew J. · director, 10% ownerOpen-market sale114,851$1.61$185KForm 4
2026-09-235AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale4,528$1.61$7KForm 4
2026-09-23Schwab Andrew J. · director, 10% ownerOpen-market sale4,528$1.61$7KForm 4
2026-09-225AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale27,612$1.65$46KForm 4
2026-09-22Schwab Andrew J. · director, 10% ownerOpen-market sale27,612$1.65$46KForm 4
2026-09-225AM Partners VII, LLC; 5AM Ventures VII, L.P.; 5AM Partners II, LLC; 5AM Ventures II LP; 5AM CO-INVESTORS II LP; DIEKMAN JOHN D; PARMAR KUSH; ROCKLAGE SCOTT M · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market sale1,088$1.65$2KForm 4
2026-09-22Schwab Andrew J. · director, 10% ownerOpen-market sale1,088$1.65$2KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 39 reporting institutions held 16.1M shares ($9.9M, 45.5% of shares outstanding).

#InstitutionSharesValue
15AM Venture Management, LLC9,681,763$6.0M
2Versant Venture Management, LLC2,007,704$1.2M
3BAKER BROS. ADVISORS LP1,575,243$968K
4VANGUARD CAPITAL MANAGEMENT LLC764,457$470K
5SPHERA FUNDS MANAGEMENT LTD.678,928$417K
6BlackRock, Inc.286,131$176K
7GEODE CAPITAL MANAGEMENT, LLC277,256$170K
8MILLENNIUM MANAGEMENT LLC258,200$159K
9PLATINUM INVESTMENT MANAGEMENT LTD233,095$143K
10VANGUARD FIDUCIARY TRUST CO104,229$64K
11STATE STREET CORP75,326$46K
12UBS Group AG45,762$28K
13XTX Topco Ltd40,919$25K
14TWO SIGMA INVESTMENTS, LP25,684$16K
15Engineers Gate Manager LP20,194$12K